Factors affecting recurrence development in stage I germ cell ovarian tumors

Yıl 2020, Cilt: 21 Sayı: 1, 1 - 5, 16.01.2020

Varol Gülseren , Mustafa Kocaer İsa Özdemir , Mehmet Gökçü Muzaffer Sancı , Kemal Güngördük

https://doi.org/10.18229/kocatepetip.439225

Öz

OBJECTIVE: To investigate the factors affecting recurrence development and time of disease-free survival in stage I malignant germ cell over tumor (MGCOT) patients.

MATERIAL AND METHODS: Records of 27 patients who received MGCOT diagnosis between January 1998 and January 2016 in the gynecology oncology clinic of Tepecik Training and Research Hospital were reviewed retrospectively. Patients with CA125 value> 35, age ≥24, patients without lymph node sampling, patients without chemotherapy, patients with tumor size> 10 cm, and capsule invasion were evaluated from prognostic factors.

RESULTS: We received 27 MGCOT patients to study. Seven (25.9%) of the patients had only surgery and 20 (74.1%) patients received adjuvant chemotherapy after surgery. All 20 patients received bleomycin, etoposide and cisplatin (BEP) protocol. Four patients (14.8%) developed recurrence. Patients with high CA125 (> 35) values and those who did not receive chemotherapy from prognostic factors were found to increase risk of relapse according to univariant logistic regression analysis. The risk factors affecting the time of disease-free survival were high CA125 and patients who did not receive chemotherapy according to Cox-regression analysis.

CONCLUSIONS: In patients with stage I malignant germ cell over tumor, high CA125 values and no adjuvant chemotherapy appear to significantly increase recurrence development and shorten disease-free survival.

KEYWORDS: Germ cell tumors; Ovarian tumors; Ovarian cancer; Ovarian germ cell tumors

Anahtar Kelimeler

Germ cell over tumor, chemotherapy, , Ovarian germ cell tumors

Evre I germ hücreli over tümörlerinde nüks gelişimine etki eden faktörler

Öz

AMAÇ: Evre I malign germ hücreli over tümörü (MGHOT) hastalarında nüks gelişimine ve hastalıksız sağkalım süresine etki eden faktörlerin araştırılmasıdır.

GEREÇ VE YÖNTEM: Tepecik Eğitim Araştırma hastanesi jinekoloji onkoloji kliniğinde Ocak 1998 – Ocak 2016 tarihleri arasında MGHOT tanısını alan ve tedavi uygulanan 27 hastanın kayıtları retrospektif olarak incelendi. Prognostik faktörlerden CA125 değeri >35, yaş ≥24, lenf nodu örneklemesi yapılmayan hastalar, kemoterapi verilmeyen hastalar, tümör boyutu >10 cm olan ve kapsül invazyonu olan hastalar değerlendirildi.

BULGULAR: Çalışamaya 27 MGHOT hastası alındı. Hastaların 7 (%25,9) tanesi sadece ameliyat olurken, 20 (%74,1) hasta ameliyat sonrası adjuvan kemoterapi aldı. 20 hastanın tamamı biliomisin, etoposid ve sisplatin (BEP) protokolünü aldı. Hastaların 4 (%14,8) tanesinde nüks gelişti. Prognostik faktörlerden yüksek CA125 (>35) değeri ve kemoterapi almayan hastaların univaryant lojistik regresyon analizine göre nüks riskini arttırdığı görüldü. Hastalıksız sağkalım süresine etki eden risk faktörü Cox-regresyon analizine göre yüksek CA125 ve kemoterapi almayan hastalardı.

SONUÇ: Evre I malign germ hücreli over tümörüne sahip hastalarda yüksek CA125 değeri ve adjuvan kemoterapi verilmemesinin nüks gelişimini anlamlı derecede arttırdığı ve hastalıksız sağkalımı kısalttığı görülmektedir.

ANAHTAR KELİMELER: Germ hücreli tümörler; Over tümörleri; Over kanseri; Overin germ hücreli tümörleri

Anahtar Kelimeler

Germ hücreli over tümörü, kemoterapi

Kaynakça

• 1. Brown J, Friedlander M, Backes F, Harter P, O’Connor D, Rouge T, Lorusso D, Maenpaa J, Kim J, Tenney M and Seckl M. Gynecologic Cancer Intergroup (GCIG) Consensus Review for Ovarian Germ Cell Tumors. Int J Gynecol Cancer; 2014;24: 48-54.
• 2. Low J, Ilancheran A, Ng J. Malignant ovarian germ-cell tumours. Best Practice & Research Clinical Obstetrics and Gynaecology; 2012; 26: 347–355.
• 3. Turkmen O, Karalok A, Basaran D, Kimyon G, Tasci T, Ureyen I, Tulunay G and Turan T. Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors. Journal of Adolescent and Young Adult Oncology; 2017; vol 6, No 2.
• 4. Zhao T, Liu Y, Jiang H, Zhang H and LU Y. Management of bilateral malignant ovarian germ cell tumors: Experience of a single institute. Molecular and Clinical Oncology; 2016; 5: 383-387.
• 5. Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. AJR Am J Roentgenol. 2016 Jun;206(6):1351-60.
• 6. Vazquez I and Rustin G. Current controversies in the management of germ cell ovarian tumours. Current Opinion Oncology; 2013; 25: 539–545.
• 7. Neeyalavira V, Suprasert P. Outcomes of Malignant Ovarian Germ-Cell Tumors Treated in Chiang Mai University Hospital over a Nine Year Period. Asian Pac J Cancer Prev; 2014; 15(12): 4909-4913.
• 8. Zhao T, Liu Y, Jiang H, Zhang H and Lu Y. Management of bilateral malignant ovarian germ cell tumors: Experience of a single institute. Molecular and Clinical Oncology; 2016; 5: 383-387.
• 9. Murugaesu N, Schmid P, Dancey G, et al. Malignant ovarian germ cell tumours: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol; 2006; 24: 4862–4866.
• 10. Lai CH, Chang TC, Hsueh S, et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynacol Oncol; 2005; 96: 784–791.
• 11. Kim J, Park J, Kim J, Kim Y, Kim Y and Nam J. The role of preoperative serum cancer antigen 125 in malignant ovarian germ cell tumors. Taiwanese Journal of Obstetrics & Gynecology; 2018; 57: 236-240.